Antigen p57/Kip2 as a potential negative regulator of human astrocytoma growth

Journal of Clinical Neuroscience

Volumn 16, Issue 12, 2009, Pages 1615-1618

  Akaishi, Kotaro ^a   Nakayama, Jun ^a   Sakai, Keiichi ^a   Kobayashi, Tatsuya ^a   Rutka, James T ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Astrocytoma; Cell proliferation; p16; p57 Kip2

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1C; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTOMA; ASTROCYTOMA CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER TISSUE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; TUMOR GROWTH;

ADULT; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P57; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70350726195     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.05.007     Document Type: Article

References (24)

1. Tsugu A., Sakai K., Dirks P.B., et al. Expression p57/Kip2 potently blocks the growth of human astrocytomas and induces cell senescence. Am J Pathol 157 (2000) 919-932
2. Sakai K., Peraud A., Mainprize T., et al. Inducible expression of p57/KIP2 inhibits glioma cell motility and invasion. J Neurooncol 68 (2004) 217-223
3. Bansal K., Liang M.L., and Rutka J.T. Molecular biology of human astrocytomas. Technol Cancer Res Treat 5 (2006) 185-194
4. Dirks P.B., Hubbard S.L., Murakami M., et al. Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines. J Neuropathol Exp Neurol 56 (1997) 291-300
5. Dirks P.B., and Rutka J.T. Current concepts in neuro-oncology: the cell cycle-a review. Neurosurgery 40 (1997) 1000-1015
6. Lee M.H., Reynisdóttir I., and Massagué J. Cloning of p57/KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9 (1995) 639-649
7. Luo Y., Hurwitz J., and Massagué J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21/Cip1. Nature 375 (1995) 159-161
8. Vaccarello G., Figliola R., Cramerotti S., et al. p57KIP2 is induced by MyoD through a p73-dependent pathway. J Mol Biol 356 (2006) 578-588
9. Cam H., Griesmann H., Beitzinger M., et al. p53 Family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 10 (2006) 281-293
10. Fan G.K., Xu F., Yang B., et al. p57(KIP2) expression is related to carcinogenesis and tumor progression in laryngeal tissues. Acta Otolaryngol 126 (2006) 301-305
11. Georgia S., Soliz R., Li M., et al. p57 and Hes1 coordinate cell cycle exit with self-renewal of pancreatic progenitors. Dev Biol 298 (2006) 22-31
12. Go J.H. Expressions of the CIP/KIP family of CDK inhibitor proteins in primary intestinal large B-cell lymphomas: correlation with clinical outcomes. Pathol Res Pract 198 (2002) 741-746
13. Hayslip J., and Montero A. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer 6 (2006) 5-44
14. Ito Y., Takeda T., Wakasa K., et al. Expression of p57/Kip2 protein in pancreatic adenocarcinoma. Pancreas 23 (2001) 246-250
15. Ito Y., Takeda T., Wakasa K., et al. Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology 61 (2001) 221-225
16. Ito Y., Yoshida H., Nakano K., et al. Expression of p57/Kip2 protein in normal and neoplastic thyroid tissue. Int J Mol Med 9 (2002) 373-376
17. Ito Y., Takeda T., Sasaki Y., et al. Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. Liver 22 (2002) 145-149
18. Ito Y., Yoshida H., Matsuzuka F., et al. Expression of the components of the Cip/Kip family in malignant lymphoma of the thyroid. Pathobiology 71 (2004) 164-170
19. Matsumoto M., Furihata M., Ohtsuki Y., et al. Immunohistochemical characterization of p57/Kip2 expression in human esophageal squamous cell carcinoma. Anticancer Res 20 (2000) 1947-1952
20. Matsuoka S., Edwards M.C., Bai C., et al. p57/KIP2, a structurally distinct member of the p21/CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9 (1995) 650-662
21. Pateras I.S., Apostolopoulou K., Koutsami M., et al. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer 119 (2006) 2546-2556
22. Popiolec D.A., Yee H., Mittal K., et al. Multiplex short tandem repeat DNA analysis confirms the accuracy of p57(KIP2) immunostaining in the diagnosis of complete hydatidiform mole. Hum Pathol 37 (2006) 1426-1434
23. Rothschild G., Zhao X., Iavarone A., et al. E proteins and Id2 converge on p57/Kip2 to regulate cell cycle in neural cells. Mol Cell Biol 26 (2006) 4351-4361
24. Stampfer M.R., Garbe J., Nijjar T., et al. Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines. Oncogene 22 (2003) 5238-5251